Modeling of Chronic Myeloid Leukemia: An Overview ofIn VivoMurine and Human Xenograft Models

Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models

Over the past years, a wide variety of in vivo mouse models have been generated in order to unravel the molecular pathology of Chronic Myeloid Leukemia (CML) and to develop and improve therapeutic approaches. These models range from (conditional) transgenic models, knock-in models, and murine bone marrow retroviral transduction models followed by transplantation. With the advancement of immunod...

Imatinib in Chronic Myeloid Leukemia: an Overview

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid leukemia (CML). Imatinib directly inhibits the constitutive tyrosine kinase activity. Imatinib binds to BCR-ABL kinase domain by preventing the transfer of a phosphate group to tyrosine on the protein substrate a...

Chronic Myeloid Leukemia : Overview and Recent Advances

The annual incidence of CML is 1.6 to 2 cases per 1,00,000 and the incidence is similar in all countries worldwide. The disease has a slight male predominance (1.4:1) and the average age at presentation is 66 years according to Surveillance, Epidemiology and End Results program (SEER). It accounts for 50-70% of leukemias in India with an annual incidence of 1-2 per lac population. The median ag...

Models of chronic myeloid leukemia

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Acute myeloid leukemia (AML) is associated with a poor survival rate, and there is an urgent need for novel and more efficient therapies, ideally targeting AML stem cells that are essential for maintaining the disease. The interleukin 1 receptor accessory protein (IL1RAP; IL1R3) is expressed on candidate leukemic stem cells in the majority of AML patients, but not on normal hematopoietic stem c...